Long-acting CCR5 Binding Agents for HIV Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies (ART) for HIV management, including pre-exposure prophylaxis (PrEP), often result in non-HIV related morbidities and unwanted side effects, necessitating the development of user-friendly regimens with simplified dosing that lack adverse effects.
Innovation Solution
Development of CCR5 binding agents, such as leronlimab, with increased effector function and circulation half-life, administered to provide long-term CCR5 receptor occupancy, thereby preventing and treating HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiretroviral therapy (ART) is used for HIV prevention and treatment, then viral replication is suppressed and HIV infection is prevented, but non-HIV related morbidities and unwanted side effects occur
Solution Approach 1:
The patent extracts and targets the specific CCR5 co-receptor that HIV uses for entry into CD4+ T cells, rather than using broad-spectrum antiretroviral drugs that affect multiple viral enzymes and cause systemic side effects. By designing antibodies that specifically bind to CCR5, the treatment achieves HIV prevention while avoiding off-target effects on human enzymes and proteins.
Solution Approach 2:
The patent introduces CCR5 binding antibodies as an intermediary substance that blocks the interaction between HIV and its target cells. The antibodies serve as mediators that bind to CCR5 receptors on CD4+ T cells, preventing HIV from attaching and entering the cells, thereby providing a physical barrier against viral infection without directly affecting viral replication machinery.
2Reliability
If frequent dosing is administered to maintain effective drug levels, then HIV prevention efficacy is maintained, but adherence becomes difficult and side effects increase
Solution Approach 1:
The patent employs periodic action by administering CCR5 binding antibodies at extended intervals (e.g., every 3 months or longer) rather than frequent daily dosing. The long-circulating antibodies maintain therapeutic levels of CCR5 blockade over months, transforming the dosing regimen from frequent short-acting administrations to rare long-acting administrations, thereby dramatically improving adherence.
Solution Approach 2:
The patent utilizes antibodies with dynamically extended half-lives through engineering modifications to the Fc region, allowing the drug to remain effective in the circulation for prolonged periods. This dynamic property enables the antibody to adapt to long-term prevention needs with minimal dosing frequency.
3Object-affected harmful factors
If short-acting CCR5 binding agents are used, then side effects are minimized, but the frequency of administration increases and adherence becomes difficult
Solution Approach 1:
The patent implements preliminary action by administering a single or infrequent dose of long-circulating CCR5 binding antibodies that pre-establish protection against HIV for extended periods. The antibodies are formulated to persist in circulation at protective levels, providing advance and sustained protection without requiring repeated administrations, thereby eliminating the time loss associated with frequent dosing.
Data Source
AI summary
The present disclosure provides CCR5 binding agents with increased effector function and circulation half-life that are useful for preventing or treating HIV.